NL-OMON42283已完成2 期
Treatment of Chronic Idiopathic Cough (CIC) and Chronic Cough in patients with Idiopathic Pulmonary Fibrosis (IPF) with PA101. - Protocol PA101-CC-02
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •COHORT 1: IDIOPATHIC PULMONARY FIBROSIS (IPF, Cohort 1);1. Male or female patients age 40 through 79 years, inclusive
- •2. Diagnosis of Idiopathic Pulmonary Fibrosis with the consensus of the multidisciplinary team based on the presence of definitive or possible usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) and after excluding alternative diagnoses, including lung diseases associated with environmental and occupational exposure, with connective tissue diseases and with drugs
- •3. Chronic cough present for at least 8 weeks and not responsive to current therapies
- •4. Daytime cough severity score on visual analogue scale > 40 mm at the Screening Visit
- •5. Daytime average cough count of at least 15 coughs per hour using objective cough
- •count monitor at the Screening Visit
- •6. Transfer capacity for carbon monoxide corrected for hemoglobin (TLCOc) > 25%
- •predicted value within 12 months of the Screening Visit and Forced Vital Capacity (FVC) > 50% predicted value within 1 month of the Screening Visit
- •7. Willingness and ability to provide written informed consent;COHORT 2: CHRONIC IDIOPATHIC COUGH (CIC, Cohort 2);1. Male or female patients age 18 through 75 years, inclusive
- •2. Chronic cough that has been present for at least 8 weeks
- •3. Diagnosis of chronic idiopathic cough (CIC) that is unresponsive to targeted treatment for identified underlying triggers (i.e., post-nasal drip, asthmatic/non-asthmatic eosinophilic bronchitis, and gastro-esophageal reflux disease)
- •4. Cough score on visual analogue scale of > 40 mm at the Screening Visit
- •5. Daytime average cough count of at least 15 coughs per hour using objective cough
- •count monitor at the Screening Visit
- •6. Willingness and ability to provide written informed consent
排除标准
- •COHORT 1: IDIOPATHIC PULMONARY FIBROSIS (IPF, Cohort 1);1. Current or recent history of clinically significant medical condition, laboratory abnormality, or illness that could put the patient at risk or compromise the quality of the study data as determined by the investigator
- •2. Significant coronary artery disease (i.e., myocardial infarction within 6 months or unstable angina within 1 month of the Screening Visit)
- •3. An upper or lower respiratory tract infection within 4 weeks of the Screening Visit
- •4. Acute exacerbation of IPF within 3 months of the Screening Visit
- •5. Long-term daily oxygen therapy (> 10 hours/day)
- •6. Presence of pulmonary arterial hypertension with limitation of activity
- •7. History of malignancy of any organ system, treated or untreated within the past 5 years, with the exception of localized basal cell carcinoma or cervix carcinoma in situ
- •8. Current or recent history (previous 12 months) of excessive use or abuse of alcohol
- •9. Current or recent history (previous 12 months) of abusing legal drugs or use of illegal drugs or substances
- •10. Participation in any other investigational drug study within 4 weeks prior to the
- •Screening Visit
- •11. Use of the following drugs within 2 weeks of the Screening Visit: Prednisone, narcotic antitussives, baclofen, gabapentin, inhaled corticosteroids, benzonatate, dextromethorphan, carbetapentane, H1 antihistamines, leukotriene modifiers, and cromolyn sodium
- •12. Females who are pregnant or breastfeeding, or if of child-bearing potential unwilling to practice acceptable means of birth control or abstinence during the study (e.g., abstinence, combination barrier and spermicide, or hormonal)
- •13. History of hypersensitivity or intolerance to cromolyn sodium;COHORT 2: CHRONIC IDIOPATHIC COUGH (CIC, Cohort 2);1. Current or recent history of clinically significant medical condition, laboratory abnormality, or illness that could put the patient at risk or compromise the quality of the study data as determined by the investigator
- •2. An upper or lower respiratory tract infection within 4 weeks of the Screening Visit
- •3. History of malignancy of any organ system, treated or untreated within the past 5 years, with the exception of localized basal cell carcinoma or cervix carcinoma in situ
- •4. Current or recent history (previous 12 months) of excessive use or abuse of alcohol
- •5. Current or recent history (previous 12 months) of abusing legal drugs or use of illegal drugs or substances
- •6. Participation in any other investigational drug study within 4 weeks prior to the Screening Visit
- •7. Use of the following drugs within 2 weeks of the Screening Visit: Prednisone, narcotic antitussives, baclofen, gabapentin, inhaled corticosteroids, benzonatate, dextromethorphan, carbetapentane, H1 antihistamines, leukotriene modifiers, and cromolyn sodium
- •8. Females who are pregnant or breastfeeding, or if of child-bearing potential unwilling to practice acceptable means of birth control or abstinence during the study (e.g., abstinence, combination barrier and spermicide, or hormonal)
- •9. History of hypersensitivity or intolerance to cromolyn sodium
研究者
相似试验
进行中（未招募）
1 期
Treatment of chronic cough with PA101.Chronic Idiopathic Cough and Chronic Cough in Idiopathic Pulmonary FibrosisMedDRA version: 18.0 Level: LLT Classification code 10066656 Term: Chronic cough System Organ Class: 100000004855EUCTR2014-004025-40-GBPatara Pharma48
进行中（未招募）
不适用
Treatment of chronic cough with PA101.EUCTR2014-004025-40-NLPatara Pharma48
已完成
2 期
Treatment of Refractory Chronic Cough With PA101Refractory Chronic CoughNCT02412020Patara Pharma52
招募中
不适用
To Control of Refractory Chronic Cough: Approach to Pathological Diversity Using Biomarkerschronic coughJPRN-UMIN000047523agoya City University50
已完成
3 期
Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With ThalidomideCoughIdiopathic Pulmonary FibrosisNCT00600028Johns Hopkins University25